派格生物医药-B(02565.HK)：就申请建议实行H股全流通向中国证监会备案

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert approximately 101.7 million unlisted shares held by 20 shareholders into H-shares based on a one-to-one ratio, which represents about 26.35% of the total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of approximately 101.7 million unlisted shares [1] - The conversion will result in these shares being transformed into H-shares, expanding the company's capital structure [1] - The application has been submitted to the China Securities Regulatory Commission for approval [1]